Roche snaps up ex-US rights to Sarepta's DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal.

Novartis sets up free lottery for $2.1m SMA drug outside US

Novartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma in countries outside the US where it is not yet approved, in a controversi

LentiGlobin gene therapy for sickle cell on course for filin...

Astellas buys gene therapy company for $3bn

Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery eff

Solid Bio hit as FDA slaps clinical hold on DMD gene therapy

Sumitomo and Roivant put flesh on bones of $3bn R&D deal